EURONEXT • Last print 1.4 years ago
$0.00—Stale · 1.4 years old
Pharnext S.A. is a biopharmaceutical company focused on developing therapies for rare neurological diseases. It leverages its proprietary platform, Pleotherapy, to identify and harness the potential synergies of multiple drugs, aiming to create novel treatments. The company's primary purpose is to address unmet medical needs in neurological disorders by repurposing existing drugs in innovative combinations, potentially accelerating development timelines and reducing costs compared to traditional drug discovery processes. Pharnext has a keen interest in conditions such as Charcot-Marie-Tooth disease and Alzheimer's, which significantly impact patients' quality of life. The company plays a strategic role in the biotechnology sector by offering hope for those with limited treatment options, thereby contributing to advancing the broader understanding of neurological disease mechanisms. With its headquarters in France, Pharnext's research and development efforts are pivotal in the European life sciences landscape, drawing interest from investors and partners aiming to support advancements in rare disease therapies."}